Influence of Age on Long-Term Outcome After Emergent Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
ABSTRACT: Background. Percutaneous coronary intervention (PCI) provides advantages compared to thrombolytic therapy in the treatment of ST-elevation myocardial infarction (STEMI). Elderly patients have increased in-hospital mortality; the predictors of adverse outcomes are not well established, with limited data available regarding late follow up of these patients. We evaluated early and late outcomes of patients undergoing emergent PCI for STEMI to identify the predictors of subsequent late adverse events and, in particular, determine if age alone was a predictor of an adverse outcome. Materials and Methods. A retrospective review of all patients referred for emergent PCI for STEMI to a single tertiary referral center was performed. All patients undergoing primary PCI for STEMI or rescue PCI for failed thrombolysis between December 2003 and December 2007 were included for assessment. Results. During the study period, 269 patients underwent primary or rescue PCI for STEMI. Patients ≥ 70 years of age were more likely to have established cardiovascular risk factors and documented coronary artery disease. Thrombolysis in myocardial infarction (TIMI) 3 flow predicted a good outcome, whereas recurrent ischemia in hospital, prior aspirin therapy and discharge creatinine predicted a poor outcome; age alone was not an adverse prognostic factor. Conclusions. The increased mortality in elderly patients undergoing PCI for STEMI reflects comorbidity and suboptimal procedural out- comes rather than any age effect per se. Future approaches to optimize the management of STEMI in the elderly should include identification of those patients most likely to benefit from an invasive approach.
J INVASIVE CARDIOL 2010;22:273–277
Primary percutaneous coronary intervention (PCI) remains the standard of care for patients presenting with ST-elevation myocardial infarction (STEMI) at centers capable for performing emergent PCI.1 PCI offers advantages in terms of recurrent ischemia and the risk of hemorrhagic stroke compared to thrombolytic therapy. There is also strong evidence supporting the use of PCI as rescue therapy in cases of failed thrombolytic therapy for STEMI,2 as well as in patients with cardiogenic shock complicating MI, including the elderly.3 However, elderly patients (> 70 years of age) are a unique population, previously underrepresented in clinical trials.4 While in-hospital mortality is noted to be higher in the elderly, the predictors of adverse outcomes are not well established. In addition, there are limited data regarding late follow up of these patients, particularly in the contemporary setting.
We sought to evaluate the early and late outcomes of elderly patients undergoing emergent PCI for STEMI and to identify the predictors of subsequent adverse events in a single tertiary referral center with primary PCI facilities.
The study was a retrospective review of all patients referred for emergent PCI for STEMI to a single tertiary referral center. All patients undergoing primary PCI for STEMI or rescue PCI for failed thrombolysis between December 2003 and December 2007 were included for assessment. Procedural data were obtained by the prospectively maintained primary PCI database at the John Hunter Hospital and based upon operator reports completed at the conclusion of each case; additional clinical data were retrieved from review of medical records as required. Femoral artery access was preferred by the operators performing primary PCI at the center, with bare-metal stents favored in accordance with institutional policy. Outcome data were obtained by review of admission codes collated through the Hunter New England Area Health Service Heart and Stroke Register, which prospectively records data on readmission and mortality from hospitals within the referral area. In those cases where data were incomplete, attempts to contact patients were made by telephone follow up.
Clinical definitions. Patients aged ≥ 70 years of age were prospectively considered elderly for the purposes of the study.5 Procedural success was angiographically defined as a residual stenosis 4.0g/L, need for transfusion of > 2 units of blood or need for corrective vascular surgery for arterial injury; acute renal failure was defined as a deterioration in renal function with an absolute increase in the serum creatinine level of > 44 μmol/l or relative increase of serum creatinine by > 25% after the administration of an intravascular contract agent. Estimated glomerular filtration rate (eGFR) was calculated using the revised Modification of Diet in Renal Disease equation.6
Statistical analysis. Statistical analysis was performed using STATA Version 10 (STATA, Inc., College Station, Texas). Comparison between patients less than or greater than 70 years of age was performed using the Student’s t-test for continuous, normally distributed variables, or the chi-square test for dichotomous variables. Mortality and recurrent MI during the follow-up period was graphed for the > 70-year-old group versus the Cox-proportional hazards regression model was used to identify the determinants of mortality and recurrent MI; variables identified in the univariate analysis with p-values
Between December 2003 and December 2007, a total of 269 patients underwent primary or rescue PCI for STEMI at our institution; of these, 87 patients (32.3%) were ≥ 70 years of age.
All surviving patients (251/269) were then followed up for a mean 1,108 days ± 437 (Range 357– 1,843) with complete clinical and procedural data available for analysis in 231 patients (85.8%).
The elderly group was more likely to be female and hypertensive, with a background of dyslipidemia, previous MI and coronary artery bypass graft (CABG) surgery when compared to the younger age group. Younger patients were more often current smokers than their older counterparts (Table 1). Fur- thermore, the elderly group were more likely to be on medical therapy (aspirin, beta-blockade, angiotensin- converting enzyme inhibition and statin agents) prior to their index presentation. There were no significant differences in terms of in-hospital use of aspirin, clopidogrel, beta-blockade, angiotensin converting enzyme inhibitors and statin agents between the two groups (Table 2).
In terms of angiographic and procedural characteristics, the infarct-related artery, stent usage, use of glycoprotein IIb/IIIa inhibition, intra-aortic balloon pump use and procedural success rates were similar between both groups, as was the frequency of post-procedural TIMI 3 flow (Table 3). The elderly were more likely to require post-procedure intensive care unit admission compared to younger patients (p = 0.1).
In-hospital mortality was lower in the younger group compared to the elderly group (3.9% vs 6.9%, p = 0.28). There were 4 strokes during hospitalization, 2 in each group (1.1% vs 2.3%, p = 0.6). Of those patients with multivessel coronary disease, 5 underwent planned revascularization during the index admission with PCI; a single patient was referred for CABG. One additional patient in the younger group underwent urgent CABG for periprocedural complications. Major bleeding complications occurred in 5 patients in the younger group and 4 patients in the elderly group (2.3% vs 4.6%, p = 0.5). Acute renal failure after PCI occurred in 8 patients in the younger age group compared to 6 patients in the elderly group, one of whom required hemodialysis (4.4% vs 6.9%, p = 0.4).
The composite outcome of recurrent MI and mortality within 30 days was higher in the elderly group (22.9% vs. 17.0%, p =0.24); most of this significance was due to the higher 30-day mortality in the elderly group (11.5% vs. 5.5%, p = 0.08). This trend continued over the long term with Kaplan Meier curves for mortality (Figure 1) differing significantly between the two groups.
In order to determine whether the differences in outcomes between the groups were due mainly to age or to other con- founders, a Cox proportional hazards regression was performed testing the effect of other variables including medications on admission and on discharge, creatinine, hemoglobin, recurrent ischemia in hospital, TIMI 3 flow post PCI, risk factors, peak creatine kinase, intensive care unit admission, door-to-balloon time, past medical history, vessel(s) involved and body mass index. Stepwise forward and backward regression results are shown in Table 4. Achieving TIMI 3 flow predicted a good outcome, whereas recurrent MI and discharge creatinine were both predictors of a poor outcome; aspirin was a marker for increased MI and mortality, probably due to bias in prescribing to higher-risk patients. Even when age was forced into the par- simonious model, the p-value was 0.325, indicating that age per se was not a risk factor for poor outcome.
In this contemporary cohort of patients, despite the use of high-dose clopidogrel loading, routine use of stents and utilization of glycoprotein IIb/IIIa inhibitors, the elderly remain at higher risk of both recurrent MI and mor- tality in both the short term (30 days) and long term (3 years) following presentation with STEMI. This reflects increased comorbidity and suboptimal pro- cedural outcomes, rather than age per se. Independent risk factors for MI and mortality included failure to achieve TIMI 3 flow, recurrent ischemia and high creatinine; age did not remain significant after adjustment for these factors.
Primary PCI remains the preferred strategy for reperfusion in patients with STEMI in whom PCI may be performed in a timely fashion by experienced operators.1 Similarly, there is strong evidence to support rescue PCI in cases of failed reperfusion after thrombolytic therapy.2 Primary PCI has been demonstrated to be superior to thrombolytic therapy in the treatment of the elderly with STEMI,7 with a previous study demonstrating a lack of survival benefit of thrombolytic therapy in those > 75 years of age.8 Furthermore, PCI offers a number of additional theoretical advantages over thrombolytic therapy in the elderly; increased age is a documented risk factor for hemorrhagic stroke after thrombolysis,9 with PCI clearly beneficial in terms of hemorrhagic stroke prevention. Advanced age is also recognized as a risk factor for cardiac rupture after thrombolytic therapy, which may reflect a reduced ability to achieve reperfusion (TIMI 3 flow) in these patients.10 As PCI is more likely to achieve TIMI 3 flow in STEMI compared to thrombolysis, it may therefore confer additional benefit in the elderly population.
Despite these potential benefits and supportive randomized
data of PCI over thrombolysis,11 the elderly are underrepresented in randomized trials, despite a disproportionately higher prevalence in the community.12 Furthermore, long-term follow up data are lacking in this population. Previous specifically designed randomized trials designed to address these issues were limited by difficulty with enrollment and short-term follow up.5
This study confirmed the importance of suboptimal proce- dural results in influencing the long-term outcome of elderly patients undergoing emergent PCI for STEMI. Failure to achieve TIMI 3 flow was demonstrated to be independently associated with subsequent mortality in our cohort. This supports previous data demonstrating that post-procedure TIMI flow grade independently influenced outcomes after PCI for acute coronary syndromes at 1 year.13 PCI in the elderly may also be associated with less satisfactory procedural outcomes, as these patients may be more likely to have significant vessel calcification and more diffuse coronary disease, which predisposes them to adverse periprocedural events.14,15
Multivariate analysis demonstrated recurrent ischemia, possibly reflecting residual coronary disease or suboptimal target lesion results, was associated with poor outcome. This observation is supported by data suggesting the presence of multivessel disease in patients undergoing culprit vessel PCI for acute coronary syndromes, including primary PCI for STEMI, is associated with a less favorable prognosis.14,16,17 The use of drug-eluting stents has been demonstrated to reduce recurrent is- chemia in patients undergoing primary PCI for STEMI18 and may offer an advantage to the elderly,19 noting the influence of recurrent ischemia on outcomes; these benefits are potentially offset by the increased risk of bleeding with prolonged dual antiplatelet therapy.20
The elderly represent a heterogenous group; there may considerable variation in comorbid status despite similarities in chronological age.12 This is supported by previous retrospective data in patients presenting with cardiogenic shock demonstrating that comorbidity influenced outcome rather than age.21 This finding, in contrast to previous randomized data, was attributed to selective use of invasive management in patients with superior functional status; to optimize results of PCI, therapy may need to be based on clinical judgement and favorable clinical characteristics, such as absence of chronic renal disease, heart failure and early presentation after symptom onset.22
That aspirin was noted to be a risk factor for adverse events during follow up may indicate that these patients were more likely to have known or suspected vascular disease. This finding is in keeping with the TIMI risk score in patients with non- STEMI, which includes aspirin use in the previous 7 days as a risk factor for adverse outcomes.23 Additionally, given the documented increased risk of cardiovascular events following bleeding, particularly after primary PCI,24,25 prior aspirin therapy and the attendant risks of gastrointestinal hemorrhage may also potentially affect outcomes. Similarly, our observation that renal impairment was a risk factor for subsequent events is consistent with previous data in patients undergoing PCI,26 including primary PCI for STEMI.27,28 Additional factors likely contributing to the less satisfactory outcomes after primary PCI include the fact that the elderly are less likely to receive evidence-based therapies following acute coronary syndromes and are at an increased risk of bleeding complications, which is known to confer an adverse prognosis after PCI.13,31
The completeness and long-term nature of the follow up provides relatively contemporary data on this poorly studied patient population.
Study limitations. Limitations of our study include the retrospective nature of the follow up, as well as the single-center nature of the review. The total number of elderly patients was small, but nonetheless represented almost one-third of the patients undergoing emergent PCI in the study period. Long-term validation of these results in a multicenter setting is important, as it is possible the included patients likely represented a selected group, with invasive treatment withheld by the treating physician in those considered to have significant comorbidity or advanced age. Furthermore, a number of these patients were
treated before the benefit of routine thrombectomy therapy was established,32 potentially affecting procedural outcomes. Finally, this study predates the introduction of bivalirudin, with the superior bleeding profile potentially offering advantages in terms of long-term outcomes.25 The utility of prasugrel,33 while offering advantages in terms of ischemic outcomes, may be limited by the incidence of hemorrhagic complications in this age group. Further study on the impact of these newer therapeutic agents in STEMI on outcomes in the elderly is warranted.
In summary, elderly patients undergoing emergent PCI with contemporary adjunctive therapy for STEMI have increased short- and long-term mortality. This reflects the presence of co- morbidity, more extensive coronary artery disease and suboptimal procedural outcomes rather than any age effect per se. These data suggest that PCI for STEMI should not be offered based on age alone, and the use of clinical assessment to identify patients most likely to benefit from an invasive strategy may optimize the results of primary PCI in the elderly. Advances in procedural and adjunctive pharmacotherapy in the manage- ment of STEMI may provide additional benefit to the elderly, with ongoing study required in order to document clinical out- comes in this increasingly important patient population.
From the *Cardiovascular Unit, John Hunter Hospital, Lookout Road, Newcastle, New South Wales, Australia, and the §Department of Epidemiology and Biostatistics, University of Newcastle, University Drive, Newcastle, New South Wales, Australia.
The authors report no financial relationships or conflict of interest disclosures re- garding the content herein.
Manuscript submitted November 20, 2009, provisional acceptance given January 4, 2010, final version March 9, 2010.
Address for correspondence: Nicholas Collins, Cardiovascular Unit, John Hunter Hospital, Newcastle, NSW, Australia, 2305. E-mail: Nicholas.Collins@hnehealth.nsw.gov.au
1. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial In- farction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117:296–329.
2. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarc- tion: A meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:422–430.
3. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with im- proved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: A report from the SHOCK Trial Registry. Eur Heart J 2003;24:828–837.
4. Holmes DR Jr, White HD, Pieper KS, et al. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol 1999;33:412–419.
5. Grines C. SENIOR-PAMI. A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. TCT 2005. October 16–21, 2005. Washington, D.C.
6. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular fil- tration rate. Ann Intern Med 2006;145:247–254.
7. de Boer MJ, Ottervanger JP, van 't Hof AW, et al. Reperfusion therapy in elderly pa- tients with acute myocardial infarction: A randomized comparison of primary an- gioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723–1728.
8. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous throm- bolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000;101:2239–2246.
9. Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802–1811.
10. Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: Observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol 1999;33:479–487.
11. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm- bolytic therapy for acute myocardial infarction: A quantitative review of 23 ran- domised trials. Lancet 2003;361:13–20.
12. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2549–2569.
13. Ndrepepa G, Mehilli J, Schulz S, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coro- nary syndromes. J Am Coll Cardiol 2008;52:512–517.
14. Parodi G, Memisha G, Valenti R, et al. Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: Results from a single centre experience. Heart 2005; 91:1541–1544.
15. Mosseri M, Satler LF, Pichard AD, et al. Impact of vessel calcification on outcomes after coronary stenting. Cardiovasc Revasc Med 2005; 6:147–153.
16. Varani E, Balducelli M, Aquilina M, et al. Single or multivessel percutaneous coro- nary intervention in ST-elevation myocardial infarction patients. Catheter Cardiovasc Interv 2008;72:927–933.
17. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion suc- cess and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007;28:1709–1716.
18. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol 2009;133:213–222.
19. Costa JR Jr, Sousa A, Moreira AC, et al. Drug-eluting stents in the elderly: Long- term (> one year) clinical outcomes of octogenarians in the DESIRE (Drug-Eluting Stents In the REal world) registry. J Invasive Cardiol 2008;20:404–410.
20. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in pa- tients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
21. Lim HS, Farouque O, Andrianopoulos N, et al. Survival of elderly patients under- going percutaneous coronary intervention for acute myocardial infarction compli- cated by cardiogenic shock. JACC Cardiovasc Interv 2009;2:146–152.
22. Hochman JS, Skolnick AH. Contemporary management of cardiogenic shock: Age is opportunity. JACC Cardiovasc Interv 2009;2:153–155.
23. Sabatine MS, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003;41:89S–95S.
24. Nikolsky E MR, Lansky A, Caixeta A, et al. Impact of gastrointestinal bleeding on outcomes of patients treated with contemporary antithrombotic strategies: Pooled analysis from 3 randomized trials. J Am Coll Cardiol 2009;53:A28
25. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218–2230. 26. Osten MD, Ivanov J, Eichhofer J, et al. Impact of renal insufficiency on angio- graphic, procedural, and in-hospital outcomes following percutaneous coronary intervention. Am J Cardiol 2008;101:780–785. 27. Marenzi G, Moltrasio M, Assanelli E, et al. Impact of cardiac and renal dysfunc- tion on inhospital morbidity and mortality of patients with acute myocardial in- farction undergoing primary angioplasty. Am Heart J 2007;153:755–762. 2
8. Bertomeu-Gonzalez V, Nunez J, Nunez E, et al. Prognostic effect of renal dysfunc- tion after ST-segment elevation myocardial infarction with and without heart fail- ure. Int J Cardiol 2006; 112:159–165.
29. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: Re- sults from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;53:1021–1030.
30. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prog- nostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007;28:1936–1945
31. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mor- tality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362–1368
32. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557–567.
33. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in pa- tients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.